GE Healthcare and Neste Jacobs form strategic alliance to drive worldwide self-sufficiency in blood plasma products

GE Healthcare and Neste Jacobs form strategic alliance to drive worldwide self-sufficiency in blood plasma products
November 22, 2011 at 03:11am

Chromatographic production of human plasma proteins factor VIII, albumin and IgG

GE Healthcare and Neste Jacobs Oy, a leading global expert in plasma fractionation plant engineering design and construction, announced today that the companies have formed a strategic alliance to assist countries worldwide to become self-sufficient in the manufacture of blood plasma products.

Human blood plasma, the liquid component of blood, is the source of many proteins such as Factor VIII, Factor IX, Immunoglobulin and Albumin. These protein products, which are prepared from plasma via a process known as fractionation, are used to treat a wide variety of serious and often life-threatening conditions such as shock, trauma, infections, immunological disorders, Hemophilia A and B, and other blood disorders.

The global demand for blood plasma products is predicted to grow from $13 billion in 2009 to an estimated $26.5 billion by 2015*. However healthcare providers in many countries, especially emerging nations, are unable to meet demand for these treatments. The World Federation of Hemophilia estimates that globally 400,000 people are living with hemophilia, of whom only 25% receive adequate treatment. Helping countries to become self-sufficient in the fractionation of locally collected plasma will overcome many of these unmet healthcare needs.

The GE Healthcare and Neste Jacobs alliance will combine GE Healthcare’s expertise in bioprocessing for plasma fractionation with Neste Jacobs’s global bio-engineering and construction capabilities. Together, the companies will offer governments and pharmaceutical companies an integrated, cost-competitive “turn-key” approach for the construction of plasma fractionation plants, to help meet the rising worldwide demand for these potentially life-saving treatments.

* BCC Research , “The Blood Industry” Market Research Report, 2011

Read more:
For more detailed information on GE Healthcare’s products for biopharmaceutical manufacture and plasma fractionation visit www.gelifesciences.com

For more detailed information on Neste Jacobs visit www.nestejacobs.com

Tags

  • (no tags available)

LEAVE A REPLY

Your comment needs to be approved by GE before it will appear. Thank you for your patience. If you have any questions, please read